Alere (ALR) volatility flat into Abbott Laboratories (ABT) agreeing to buy at $51 per share rather than previous offer of $56
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alere (ALR) PT Lowered to $51 at Canaccord Genuity
April 17, 2017 9:27 AM EDTCanaccord Genuity lowered its price target on Alere (NYSE: ALR) to $51.00 (from $52.00) while maintaining a Buy rating. ABT and ALR announced a settlement at $51/share, or ~21% higher than ALR's closing price of $42.31 last Thursday.
Canaccord believes that shareholders would have approved anything at $50+ so... More
Alere (ALR) PT Lowered to $51 at Jefferies Following Announced Revisions to ABT Merger
April 17, 2017 7:17 AM EDTJefferies lowered its price target on Alere (NYSE: ALR) to $51.00 (from $56.00) while maintaining a Hold rating following the company's announced amended the terms of to the merger with ABT.
Key revisions include: 1) $51/share vs. the original $56; 2) timeline extended to September 30 from April 30; and... More
